Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426124 · ClinicalTrials.gov registry record
An International Pulmonary Embolism Registry Using EKOS
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 1,480
- Enrollment target
NCT03426124 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,480 participants.
The verdict
NCT03426124 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 1,480 participants
- Enrollment target
Study Summary
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.
Interventions
- DEVICE EkoSonic Endovascular System with thrombolytic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,480 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2020-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426124
The ClinicalTrials.gov registry entry for NCT03426124 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EkoSonic Endovascular System with thrombolytic is the first listed.
NCT03426124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03426124 about?
NCT03426124 is a clinical study titled "An International Pulmonary Embolism Registry Using EKOS". This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.
What is the current status of trial NCT03426124?
This trial is currently completed. The enrollment target is 1,480 participants. The study started on 2018-03-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03426124?
The interventions under investigation include: EkoSonic Endovascular System with thrombolytic (DEVICE).
Who is sponsoring clinical trial NCT03426124?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.